What is the value of extending someone’s life for a year? How does that compare to a cure, while also compensating drug developers for their painstaking efforts? ICER, the nonprofit founded by physician and bioethicist Pearson, has become perhaps the most prominent independent arbiter on the critical issue of fair drug pricing, with its findings increasingly impacting what payers are willing to shell out for drugs. ICER recently weighed in on lecanemab, the closely watched Alzheimer’s drug from Eisai and Biogen granted accelerated approval by the FDA in January and now sold as Leqembi. In its December draft evidence report, ICER said lecanemab would be fairly priced at between $8,500 and $20,600 per year — under the $26,500 price set by Eisai.
More in Nonprofit
Nonprofit
Juan Acosta
LGBTQ+ mental health advocate
Nonprofit
Vanessa Grubbs
Founder and president, Black Doc Village
Nonprofit
Alexis McGill Johnson
President & CEO, Planned Parenthood
Nonprofit
Nelya Melnitchouk
Co-founder and CEO, Global Medical Knowledge Alliance
Nonprofit
Jim O’Connell
President, Boston Health Care for the Homeless Program
Nonprofit
Jason Resendez
President and CEO, National Alliance for Caregiving